设为首页         

资讯内容 Content

[ESC2010]Sanjit Jolly ESC 2010 Interview
国际循环网版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

 编辑:国际循环网 时间:2010/10/13 11:49:38    加入收藏
 关键字:Sanjit Jolly   STE-ACS   OASIS 5研究  磺达肝癸钠 依诺肝素 

    <International Circulation>: The OASIS 5 study compared fondaparinux with enoxaparin in patients with STE-ACS and the OASIS 6 study compared fondaparinux with UFH in patients with STEMI. Both of those studies confirmed the safety and efficacy of fondaparinux. The OASIS 8 study compared fondaparinux with UHF during PCI in high risk patients with non-STE-ACS. From the results of these trials and your own experience, what is your understanding of the best anticoagulant strategy for patients presenting with ACS?

 《国际循环》:OASIS 5研究在STE-ACS患者中将磺达肝癸钠与依诺肝素进行了比较,OASIS 6研究则在STEMI患者中对比了磺达肝癸钠和UFH。这些研究均证实了磺达肝癸钠的安全性和有效性。OASIS-8研究在非STE-ACS高危患者PCI期间比较了磺达肝癸钠和UFH。从这些试验的结果以及您个人的经验来看,对ACS患者最佳抗凝策略您有何理解?

    Prof. Jolly: Fondaparinux is an attractive option that is recommended by the guidelines and it is in fact a safe option. Now you have clear recommendations how to treat these patients in the cath lab. You can have a seamless strategy with therapy in the emergency room, to the cath lab, and home. If I were a patient, I would think this were an attractive option.

    Jolly教授:磺达肝癸钠是一个得到指南推荐的有吸引力的选择,实际上也是一个安全的选择。目前,关于在导管室中如何治疗这些患者已经有了明确的推荐。在急诊室、导管室以及家庭中,我们已有一种无缝治疗策略。如果我是一名患者,我会认为这是一个有吸引力的选择。



[1]  [2]  [3]  下一页

注册

网友评论仅供其表达个人看法,并不表明国际循环同意其观点或证实其描述。 发表评论需登陆

 
关于本站 | 设为首页 | 加入收藏 | 站长邮箱 | 友情链接 | 版权申明

国际循环 版权所有  2008-2010 icirculation.com  All Rights Reserved